Contents

Current Cancer Drug Targets, Volume 6 - Number 8

Mechanisms of Resistance to Imatinib in CML Patients: A Paradigm for the Advantages and Pitfalls of Molecularly Targeted Therapy

, 6(8): 645 - 657

E. Ritchie and G. Nichols


DOI: 10.2174/156800906779010209




Can we Target the Chemokine Network for Cancer Therapeutics?

, 6(8): 659 - 670

Ryan Giles and Robert D. Loberg


DOI: 10.2174/156800906779010245




The JAK-STAT Pathway: A Therapeutic Target in Hematological Malignancies

, 6(8): 671 - 679

A. Ferrajoli, S. Faderl, F. Ravandi and Z. Estrov


DOI: 10.2174/156800906779010227




Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids

, 6(8): 681 - 689

Nam Deuk Kim, Eunok Im, Young Hyun Yoo and Yung Hyun Choi


DOI: 10.2174/156800906779010236




EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer

, 6(8): 691 - 710

Igor Astsaturov, Roger B. Cohen and Paul M. Harari


DOI: 10.2174/156800906779010191




Chemopreventive Agents Alters Global Gene Expression Pattern: Predicting their Mode of Action and Targets

, 6(8): 711 - 727

Bhagavathi A. Narayanan


DOI: 10.2174/156800906779010218




Anti-Invasive and Anti-Metastasis Strategies: New Roads, New Tools and New Hopes

, 6(8): 729 - 751

Laurent Dolle, Herman T. Depypere and Marc E. Bracke


DOI: 10.2174/156800906779010263




ERRATUM

, 6(8): 753


DOI: 10.2174/156800906779010254




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science